High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

Completed · Phase 2/Phase 3

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.

Key facts

Study ID
NCT00297947
Run by
Manhattan Psychiatric Center
People needed
60
Starts
2004-12-01
Expected to finish
2014-10-01
Last updated by the study team
2015-04-17

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.